Introduction Tigertriever stent-retriever (Rapid Medical, Israel) is a device designed using a different approach compared to classical stent-retrievers (i.e. Solitare or pRESET). The Tigetriever is an adjustable device that provides manual control of its diameter and curvature during stroke endovascular treatment.

Aim of Study To compare the efficacy and safety of Tigertriever (adjustable stent-retriever) to stent-like stent-retrievers (SolitaireX and pRESET) in a retrospective single-center study using propensity score analysis.

Methods Patients treated in a comprehensive stroke center due to large vessel occlusion acute ischemic stroke between January 2016 and August 2021 were evaluated. Baseline characteristics and treatment results were compared between these groups before and after pair matching. There were 140 patients (60 in Tigertriever group and 80 in the stent-like stent-retriever group). In propensity score analysis, 52 matched pairs were selected in Tigertriever and stent-like stent-retriever groups.

Results The Tigertriever group had a higher successful first pass revascularization rate [46 vs. 23%, OR (95% CI): 1.7 (1.1–2.9), p = 0.013] and 14-min shorter groin-to-revascularization time (51 vs. 65 min. p = 0.017). There were no significant differences between Tigertriever and stent-like stent-retriever groups in the following: favorable mRS at 3 months, favorable recanalization rate, and symptomatic intracranial hemorrhages. There were no observed periprocedural adverse events related to Tigertriever, SolitaireX, or pRESET.

Conclusion Tigertriever had a significantly higher successful first pass revascularization rate and shorter groin-to-revascularization time in the analysis done before and after propensity score matching with stent-like stent-retrievers.

Disclosure of Interest Nothing to disclose